|Mr. Corey N. Fishman||Pres, CEO & Director||803.48k||N/A||1965|
|Ms. Judith M. Matthews||Chief Financial Officer||432.88k||N/A||1970|
|Dr. Michael W. Dunne||Chief Scientific Officer||549.06k||N/A||1960|
|Mr. Benjamin M. Pe||VP of Operations||N/A||N/A||N/A|
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.